Iceland· IS-EU/1/12/797/004
Eylea
A aflibercept product containing afliberceptum inn, registered in Iceland by Bayer AG*. The same ATC class is registered in 11 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Aflibercept is registered in 11 of 19 countries.
Countries holding a registration under ATC S01LA05 (aflibercept), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Aflibercept · ATC S01LA05
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Afliberceptum INN
- Manufacturer
- Bayer AG*
- Country
- Iceland (IS)
- ATC code
- S01LA05
- ATC class
- Aflibercept
- Defined daily dose
- 0.018 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 2
2 priced- ean0498541 hgl x1 pakkiISK 127552
- ean4243041 áf.spr x1 pakkiISK 124668
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aflibercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumEylea 114.3 mg/mlBayer
- CzechiaEYLEABayer AG, Leverkusen
- SpainEYLEA 114,3 MG/ML SOLUCION INYECTABLEBayer Ag
- FranceEYLEA 114,3 mg/mL, solution injectableBAYER AG (ALLEMAGNE)
- IrelandEylea 114.3 mg/ml solution for injectionBayer AG
- SwedenEylea 114,3 mg/ml Injektionsvätska, lösningBayer AG
- NetherlandsEylea 114,3 mg/ml oplossing voor injectieBayer AG
- NorwayEyleaBayer AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Vgenfli
- Liechtenstein · Afiveg, Afqlir
- Norway · Afiveg, Afqlir
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ece86272-f3d4-485f-9123-6776dbbea4a0 GET /v1/drugs/ece86272-f3d4-485f-9123-6776dbbea4a0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn í áfylltri sprautu",
"source": "lyfjastofnun",
"atc_raw": "S01LA05",
"marketed": true,
"strength": "114,3 mg/ml",
"ma_number": "EU/1/12/797/004",
"substance": "Afliberceptum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45535"
}See everything about aflibercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.